LUCILLE THOMAS: Open Payments
NPI 1114995768 · AGOURA HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,402 in 52 payments from 13 companies in 2025. Trend: 2023 $759 · 2024 $912 · 2025 $1,402
Food & beverage: $1,303Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $566 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $199 |
| Astellas Pharma US Inc | 4 | $184 |
| Lilly USA, LLC | 5 | $93 |
| Amgen Inc. | 3 | $77 |
| GlaxoSmithKline, LLC. | 3 | $61 |
| Indivior Inc. | 2 | $50 |
| Alkermes, Inc. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $31 |
Products named: VRAYLAR, CAPLYTA, QULIPTA, MOUNJARO, Veozah, OTEZLA, TRELEGY ELLIPTA, SUBLOCADE.
Industry payments across CA — which companies pay providers there.
